Essand M - Search Results

1

A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia.

Enblad G, Karlsson H, Gammelgård G, Wenthe J, Lövgren T, Amini RM, Wikstrom KI, Essand M, Savoldo B, Hallböök H, Höglund M, Dotti G, Brenner MK, Hagberg H, Loskog A. Enblad G, et al. Among authors: essand m. Clin Cancer Res. 2018 Dec 15;24(24):6185-6194. doi: 10.1158/1078-0432.CCR-18-0426. Epub 2018 Aug 10. Clin Cancer Res. 2018. PMID: 30097433 Clinical Trial.

2

CD4⁺ T cell-induced inflammatory cell death controls immune-evasive tumours.

Kruse B, Buzzai AC, Shridhar N, Braun AD, Gellert S, Knauth K, Pozniak J, Peters J, Dittmann P, Mengoni M, van der Sluis TC, Höhn S, Antoranz A, Krone A, Fu Y, Yu D, Essand M, Geffers R, Mougiakakos D, Kahlfuß S, Kashkar H, Gaffal E, Bosisio FM, Bechter O, Rambow F, Marine JC, Kastenmüller W, Müller AJ, Tüting T. Kruse B, et al. Among authors: essand m. Nature. 2023 Jun;618(7967):1033-1040. doi: 10.1038/s41586-023-06199-x. Epub 2023 Jun 14. Nature. 2023. PMID: 37316667 Free PMC article.

3

Adenovirus CD40 ligand gene therapy counteracts immune escape mechanisms in the tumor Microenvironment.

Loskog A, Dzojic H, Vikman S, Ninalga C, Essand M, Korsgren O, Totterman TH. Loskog A, et al. Among authors: essand m. J Immunol. 2004 Jun 1;172(11):7200-5. doi: 10.4049/jimmunol.172.11.7200. J Immunol. 2004. PMID: 15153545

4

CpG oligonucleotide therapy cures subcutaneous and orthotopic tumors and evokes protective immunity in murine bladder cancer.

Ninalga C, Loskog A, Klevenfeldt M, Essand M, Tötterman TH. Ninalga C, et al. Among authors: essand m. J Immunother. 2005 Jan-Feb;28(1):20-7. doi: 10.1097/00002371-200501000-00003. J Immunother. 2005. PMID: 15614041

5

The immunotherapy of prostate and bladder cancer.

Totterman TH, Loskog A, Essand M. Totterman TH, et al. Among authors: essand m. BJU Int. 2005 Oct;96(5):728-35. doi: 10.1111/j.1464-410X.2005.05772.x. BJU Int. 2005. PMID: 16144528

6

Adenovirus-mediated CD40 ligand therapy induces tumor cell apoptosis and systemic immunity in the TRAMP-C2 mouse prostate cancer model.

Dzojic H, Loskog A, Tötterman TH, Essand M. Dzojic H, et al. Among authors: essand m. Prostate. 2006 Jun 1;66(8):831-8. doi: 10.1002/pros.20344. Prostate. 2006. PMID: 16491482

7

CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity.

Mangsbo SM, Ninalga C, Essand M, Loskog A, Tötterman TH. Mangsbo SM, et al. Among authors: essand m. J Immunother. 2008 Jan;31(1):34-42. doi: 10.1097/CJI.0b013e3181587d29. J Immunother. 2008. PMID: 18157010

8

Midgut carcinoid patients display increased numbers of regulatory T cells in peripheral blood with infiltration into tumor tissue.

Vikman S, Sommaggio R, De La Torre M, Oberg K, Essand M, Giandomenico V, Loskog A, Totterman TH. Vikman S, et al. Among authors: essand m. Acta Oncol. 2009;48(3):391-400. doi: 10.1080/02841860802438495. Acta Oncol. 2009. PMID: 18855160

9

CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery.

Fransson M, Piras E, Burman J, Nilsson B, Essand M, Lu B, Harris RA, Magnusson PU, Brittebo E, Loskog AS. Fransson M, et al. Among authors: essand m. J Neuroinflammation. 2012 May 30;9:112. doi: 10.1186/1742-2094-9-112. J Neuroinflammation. 2012. PMID: 22647574 Free PMC article.

10

Genetically engineered T cells for the treatment of cancer.

Essand M, Loskog AS. Essand M, et al. J Intern Med. 2013 Feb;273(2):166-81. doi: 10.1111/joim.12020. J Intern Med. 2013. PMID: 23198862 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

113 results

Search Page